Free Trial

Bicara Therapeutics (BCAX) Competitors

Bicara Therapeutics logo
$11.88 -0.70 (-5.56%)
Closing price 06/11/2025 04:00 PM Eastern
Extended Trading
$11.89 +0.01 (+0.08%)
As of 06/11/2025 07:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BCAX vs. NAMS, BLTE, HRMY, KNSA, VCEL, DNLI, CGON, VERA, GMTX, and IMCR

Should you be buying Bicara Therapeutics stock or one of its competitors? The main competitors of Bicara Therapeutics include NewAmsterdam Pharma (NAMS), Belite Bio (BLTE), Harmony Biosciences (HRMY), Kiniksa Pharmaceuticals (KNSA), Vericel (VCEL), Denali Therapeutics (DNLI), CG Oncology (CGON), Vera Therapeutics (VERA), Gemini Therapeutics (GMTX), and Immunocore (IMCR). These companies are all part of the "pharmaceutical products" industry.

Bicara Therapeutics vs. Its Competitors

Bicara Therapeutics (NASDAQ:BCAX) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends, community ranking and profitability.

89.9% of NewAmsterdam Pharma shares are held by institutional investors. 15.5% of Bicara Therapeutics shares are held by company insiders. Comparatively, 20.8% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Bicara TherapeuticsN/A N/A N/A
NewAmsterdam Pharma N/A N/A N/A

NewAmsterdam Pharma received 14 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. Likewise, 90.91% of users gave NewAmsterdam Pharma an outperform vote while only 76.19% of users gave Bicara Therapeutics an outperform vote.

CompanyUnderperformOutperform
Bicara TherapeuticsOutperform Votes
16
76.19%
Underperform Votes
5
23.81%
NewAmsterdam PharmaOutperform Votes
30
90.91%
Underperform Votes
3
9.09%

Bicara Therapeutics presently has a consensus target price of $31.86, suggesting a potential upside of 168.17%. NewAmsterdam Pharma has a consensus target price of $43.00, suggesting a potential upside of 109.76%. Given Bicara Therapeutics' higher possible upside, equities analysts clearly believe Bicara Therapeutics is more favorable than NewAmsterdam Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bicara Therapeutics
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.00
NewAmsterdam Pharma
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

Bicara Therapeutics has higher earnings, but lower revenue than NewAmsterdam Pharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bicara TherapeuticsN/AN/AN/AN/AN/A
NewAmsterdam Pharma$47.14M48.82-$176.94M-$1.88-10.90

In the previous week, NewAmsterdam Pharma had 19 more articles in the media than Bicara Therapeutics. MarketBeat recorded 31 mentions for NewAmsterdam Pharma and 12 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 1.10 beat NewAmsterdam Pharma's score of 0.53 indicating that Bicara Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bicara Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
NewAmsterdam Pharma
10 Very Positive mention(s)
1 Positive mention(s)
13 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

NewAmsterdam Pharma beats Bicara Therapeutics on 6 of the 9 factors compared between the two stocks.

Get Bicara Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCAX vs. The Competition

MetricBicara TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$647.89M$6.85B$5.57B$8.62B
Dividend YieldN/A2.56%5.28%4.18%
P/E RatioN/A8.7827.1720.06
Price / SalesN/A255.64409.72157.10
Price / CashN/A65.8538.2534.64
Price / BookN/A6.557.064.70
Net IncomeN/A$143.93M$3.23B$247.88M
7 Day Performance7.71%3.97%2.89%2.66%
1 Month Performance-16.28%11.32%9.06%6.40%
1 Year PerformanceN/A4.20%31.40%14.07%

Bicara Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCAX
Bicara Therapeutics
2.3353 of 5 stars
$11.88
-5.6%
$31.86
+168.2%
N/A$647.89MN/A0.0032Positive News
Analyst Revision
NAMS
NewAmsterdam Pharma
2.9856 of 5 stars
$18.93
+4.5%
$43.00
+127.2%
+3.2%$2.13B$47.14M-10.074Trending News
Analyst Forecast
Analyst Revision
BLTE
Belite Bio
2.2911 of 5 stars
$65.02
+0.2%
$96.67
+48.7%
+25.2%$2.07BN/A-58.5810Short Interest ↑
Analyst Revision
HRMY
Harmony Biosciences
4.7728 of 5 stars
$35.56
+3.1%
$53.00
+49.0%
+18.4%$2.04B$744.85M16.85200Positive News
Short Interest ↑
Analyst Revision
KNSA
Kiniksa Pharmaceuticals
3.2478 of 5 stars
$27.92
+2.0%
$38.80
+39.0%
+61.1%$2.04B$481.17M-199.41220Trending News
Insider Trade
VCEL
Vericel
2.67 of 5 stars
$40.46
-2.0%
$61.14
+51.1%
+2.0%$2.04B$238.54M674.45300Positive News
High Trading Volume
DNLI
Denali Therapeutics
4.3524 of 5 stars
$13.96
+5.4%
$33.71
+141.5%
-29.7%$2.03B$330.53M-5.06430Positive News
Analyst Revision
High Trading Volume
CGON
CG Oncology
2.4986 of 5 stars
$26.59
+3.8%
$58.22
+119.0%
-25.6%$2.03B$662K-17.6161Positive News
Analyst Revision
VERA
Vera Therapeutics
2.8949 of 5 stars
$31.74
+67.5%
$65.00
+104.8%
-42.5%$2.02BN/A-12.1640Short Interest ↑
Analyst Revision
Gap Up
High Trading Volume
GMTX
Gemini Therapeutics
N/A$46.68
-0.4%
N/A+33.6%$2.02BN/A-46.6830High Trading Volume
IMCR
Immunocore
2.9124 of 5 stars
$38.65
+5.6%
$58.89
+52.4%
-13.5%$1.94B$333.58M-40.68320Positive News
Analyst Revision
High Trading Volume

Related Companies and Tools


This page (NASDAQ:BCAX) was last updated on 6/12/2025 by MarketBeat.com Staff
From Our Partners